Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$31.38 USD

31.38
3,352,548

-0.02 (-0.06%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $31.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Buy Stocks for January 10th

by Zacks Equity Research

PCRFY, IMCR, CPRX, AMPX and ENS have been added to the Zacks Rank #1 (Strong Buy) List on January 10, 2024.

Zacks Equity Research

If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Is Catalyst Pharmaceuticals (CPRX) Stock a Solid Choice Right Now?

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up

by Zacks Equity Research

Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.

Zacks Equity Research

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalyst's (CPRX) third-quarter 2023 earnings are expected to have been driven by the robust performances of its two marketed drugs, Firdapse and Fycompa CIII.